Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]

Published March 10, 2022

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]

Published April 9, 2024

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Published November 1, 2018

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University